Participants 103 153 3
patients with advanced non-small-cell lung cancer.
Participants 163 284 4
New effective chemotherapy is needed to improve the outcome of patients with advanced non-small-cell lung cancer (NSCLC).
Participants 440 727 7
PATIENTS AND METHODS Between January 1995 and April 1996, 414 patients with stage IIIB or IV NSCLC were randomized to received either a control arm of high-dose cisplatin (100 mg/m(2)) or a combination of paclitaxel (175 mg/m(2), 3-hour infusion) and cisplatin (80 mg/m(2)) every 21 days
